Influential drivers of the cost-effectiveness of respiratory syncytial virus vaccination in European older adults: A multi-country analysis

Competing Interest Statement

Outside the submitted work, PB declares funding received by his institute from Merck for research on varicella zoster and Pfizer for research on pneumococcus vaccine, XL declares funding received by her institute from Icosavax, but they have not received any personal fees or other personal benefits. CKJ reports a research grant from Nordsjallands Hospital, travel grants from the University of Copenhagen, William Demants Fond in Denmark, and the European Society of Clinical Virology and expert consultation fees from Sanofi, outside of the submitted work. Outside the submitted work, HN declares consulting fees received from WHO, Pfizer, Bill and Medlinda Bill and Melinda Gates Foundation and Sanofi, honoraria for lectures/presentations from Astra Zeneca, GSK and Pfizer paid to his institution, travel grants from Pfizer and Sanofi, and participation on a Data Safety Monitoring Board or Advisory Board of GSK, Sanofi, Merck, Icosavax, Pfizer (paid to his institution), as well as WHO and ResViNET (unpaid). AUF declares grants/contracts from Moderna and VAC4EU paid to her institution, outside submitted work. AOS and JDD declares grants/contracts from Moderna, MSD and GSK paid to their institution, outside submitted work. AOS also declares consultancy fees from GSK and Moderna, outside submitted work. JDD declares consultancy fees and honoraria from GSK, Pfizer and MSD, and travel grants from Sanofi and GSK, outside the submitted work. HS declares attending Adult Immunization Board meetings twice a year, the meetings (and travel) are funded by an unrestricted grant from Vaccines Europe, outside submitted work. LW declares grants received from Research Foundation Flanders (FWO), Antwerp University Research Council and Horizon Europe 2.1 Health paid to his institute, outside the submitted work. MJ declares research grants from NIHR, RCUK, BMGF, WHO, Gavi, Wellcome Trust, European Commission, InnoHK, TFGH, CDC, Gates Foundation paid to his institution, outside the submitted work. Other authors declared no competing interests.

Funding Statement

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement number 101034339. The JU receives support from the European Union's Horizon 2020 research and innovation program and European Federation of Pharmaceutical Industries Associations. MJ received funding from the NIHR Health Protection Research Units in Modelling and Health Economics (NIHR200908) and Immunisation (NIHR200929). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes